Clinical Trial Update: Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating olanzapine or dexamethasone, with a 5-HT3 receptor antagonist and an NK-1 receptor antagonist, for preventing chemotherapy-induced na…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• olanzapine (olanzapine)

Snippet

Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University | Conditions: Chemotherapy-induced Nausea and Vomiting | Phase 3 | Status: COMPLETED